Cargando…
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
Raltegravir is the first licensed compound in 2007 of the new integrase inhibitor drug class. At the dose of 400 mg twice daily, raltegravir showed a potent antiviral action in antiretroviral-naïve patients when associated with tenofovir and emtricitabine. Raltegravir was also found to be highly act...
Autores principales: | Charpentier, Charlotte, Weiss, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108740/ https://www.ncbi.nlm.nih.gov/pubmed/21694899 http://dx.doi.org/10.2147/IDR.S8673 |
Ejemplares similares
-
Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011) -
Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009) -
HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009) -
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010) -
Raltegravir: The evidence of its therapeutic value in HIV-1 infection
por: Ramkumar, Kavya, et al.
Publicado: (2010)